Month: March 2024

FY 2023 Record Revenue Increased 84% to $6.0 Million FY 2023 Gross Profit Increased 93% to $1.9 Million BREA, Calif., March 28, 2024 (GLOBE NEWSWIRE) — Reborn Coffee, Inc. (NASDAQ: REBN) (“Reborn”, or the “Company”), a California-based retailer of specialty coffee, has reported its financial and operational results for the fiscal year ended December 31, 2023. Key Financial and Operational HighlightsRevenue increased 109% to $1.8 million in Q4’23 from $0.9 million in Q4’22. Revenue increased 84% to $6.0 million in FY’23 from $3.2 million in FY’22. Ended FY’23 with 14 open locations, with one location in development. Company-operated store sales increased to $5.7 million, or 79%, in the year ended December 31, 2023, compared to the same period in 2022. Company-operated store...

DALLAS, March 28, 2024 (GLOBE NEWSWIRE) — Psychemedics Corporation (NASDAQ: PMD), the world’s leading provider of hair testing for drugs of abuse, announced today financial results for the year ended December 31, 2023. “2023 proved to be another challenging year due to the negative impact of major economic forces. The labor shortage continues and remains unprecedented in its severity and duration, having an adverse impact on our clients. Despite these challenges, my confidence in our potential continues to increase. As cost reductions from Q4 continue to materialize, we will start our pursuit of new markets and new applications for our hair testing science to create value for clients and shareholders,” stated Brian Hullinger, Chief Executive Officer of Psychemedics. “Leveraging our expertise and reputation for accuracy combined...

On track for topline data from CAN-2409 phase 3 in localized intermediate/high risk prostate cancer, expected in Q4 2024Results from ongoing, first-in-human, phase 1b clinical trial of CAN-3110, in recurrent high-grade glioma, published in NatureCatalyst-rich 2024 paves way for transformational yearNEEDHAM, Mass., March 28, 2024 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today reported financial results for the fourth quarter and year ended December 31, 2023, and provided a corporate update. “2023 was a significant year for Candel with two additional FDA Fast Track Designations for CAN-2409 for non-small cell lung cancer and borderline resectable pancreatic...

Full Year 2023 Net Revenue Increased 80% from 2022 While OPEX Decreased 33% Twirla Demand and Factory Sales Up 121% and 114% Respectively in 2023 vs 2022 Company Completes Pay-Off of Debt Facility in First Quarter 2024 Twirla Demand Expected to Rebound in First Quarter 2024 from Decreased Demand in Fourth Quarter 2023 Management to Host Conference Call Today, Thursday, March 28, 2024 at 8:30 a.m. ET PRINCETON, N.J., March 28, 2024 (GLOBE NEWSWIRE) — Agile Therapeutics, Inc. (Pink: AGRX), a women’s healthcare company, today reported financial results for the three and twelve months ended December 31, 2023 and provided a corporate update. “2023 was a year for Agile that we believe demonstrated our ability to continue to grow Twirla,” said Agile Therapeutics Chairperson and Chief Executive Officer Al Altomari. “We believe we...

SEATTLE, March 28, 2024 (GLOBE NEWSWIRE) — Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today provided a business update and announced fiscal year 2023 financial results for the period ended December 31, 2023.  “We made tremendous progress during 2023 in building a fully integrated radiopharmaceuticals company dedicated to advancing potentially best- or first-in-class alpha-particle therapies,” said Thijs Spoor, Perspective Therapeutics’ CEO. “We are pleased with our continued momentum into 2024. In March 2024, we acquired a radiopharmaceutical manufacturing facility to support production expansion, and we added to our strategic partnerships to include pioneers in radiopharmaceuticals and oncology such...

2023 OvaSuite revenue of $9.2 million, an increase of 15% year-over-year 2023 OvaSuite volume of 23,990 units, an increase of 12% year-over-year Cash utilization declined in both the fourth quarter and full-year 2023 to $3.5 million and $15.9 million, respectively Conference Call and Webcast scheduled for today at 8:30 am ET AUSTIN, Texas, March 28, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today reported its financial results for the fourth quarter and year ended December 31, 2023. “We made a great deal of progress in 2023. Not only were we able to cut our cash used in operations in half by aligning spending to business needs, but we simultaneously increased revenues...

M3+ Delinquency Rate by VintageM3+ Delinquency Rate by Vintage — Full Year Revenue Grew 67.1% to RMB5,467 million — — Full Year Net Income Grew 9.9% to RMB1,298 million — SHANGHAI, China, March 28, 2024 (GLOBE NEWSWIRE) — Jiayin Group Inc. (“Jiayin” or the “Company”) (NASDAQ: JFIN), a leading fintech platform in China, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2023. Fourth Quarter 2023 Operational and Financial Highlights:Loan facilitation volume1 was RMB20.1 billion (US$2.8 billion), representing an increase of 6.3% from the same period of 2022.Average borrowing amount per borrowing was RMB9,944 (US$1,401), representing a decrease of 8.6% from the same period of 2022.Repeat borrowing rate2 was 72.9%, compared with 67.2% in...